Kevin Gardner, MD
Family Medicine · Layton, UTNPI 1790897452
Payments from drug & device makers
Across 450 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Amarin Pharma, Inc.$471
- AstraZeneca$423
- Boehringer Ingelheim$395
- Lilly USA, LLC$314
- plus $3K from 49 others
Across 4 payments — averaging $454.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$1,20014%
- Travel & lodging$1,10513%
- Food & beverage$6,22173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$8,527 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $59,289 |
| EliquisApixaban | 74 | $55,571 |
| JardianceEmpagliflozin | 54 | $44,763 |
| MyrbetriqMirabegron | 44 | $30,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $28,290 |
| CaplytaLumateperone Tosylate | 14 | $27,007 |
| JanuviaSitagliptin Phosphate | 17 | $20,979 |
| RybelsusSemaglutide | 14 | $20,827 |
| LinzessLinaclotide | 30 | $20,592 |
| TrulicityDulaglutide | 18 | $17,207 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $14,550 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,067 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $13,876 |
| FarxigaDapagliflozin Propanediol | 19 | $13,347 |
| TrulancePlecanatide | 13 | $11,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $55 | $80,11774 claims |
| PfizerEliquis, Nurtec Odt | $142 | $69,63888 claims |
| Boehringer IngelheimJardiance | $395 | $44,76354 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $133 | $33,38151 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $30,76544 claims |
| MerckJanuvia, Belsomra | $78 | $29,86435 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $314 | $28,87129 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $423 | $27,89732 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $58 | $27,00714 claims |
| AbbVieLinzess | $2,308 | $20,59230 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $189 | $11,92113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $151 | $8,11515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.
Other family medicine in Layton
- Marc AndersonLayton$2.8M
- Jeffery DegrauwLayton$921K
- Kurtis WoolfLayton$224K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.